A growing number of healthcare systems are moving to self-distribution — where they order products directly from manufacturers and handle their own storage and order fulfillment.
Concerns about quality control and data integrity have focused on companies in India and China, where more and more ingredients used in medicine for the U.S. are being made. But those concerns aren’t limited to overseas factories, according to a year-long investigation into FDA’s regulation of the generic-drug industry.